tirzepatide mc4r deficient efficacy
7 Reasons Tirzepatide Outperforms Semaglutide in MC4R-Deficient Patients
Tirzepatide delivers a 25% greater BMI reduction than semaglutide in MC4R-deficient patients, offering a stronger weight-loss signal at comparable dosing intervals. In clinical trials the drug shaved an additional 1.6 points off average BMI, while maintaining a tolerable safety profile. This early advantage explains why many endocrinologists are shifting